Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer

Head and Neck

Volumn 32, Issue 9, 2010, Pages 1178-1184

  Pastorcic Grgic, Marija ^a   Sarcevic, Bozena ^a   Dosen, Danijel ^a   Juretic, Antonio ^b   Spagnoli, Giulio C ^c   Grgic, Marko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

MAGE A; NY ESO 1; pharyngeal cancer; prognosis

Indexed keywords

CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 57B; MONOCLONAL ANTIBODY B9.8.1.1; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78349285539     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21314     Document Type: Article

References (40)

1. Parkin DM, Whelan S, Ferlay J, Raymond L, Young J,. Cancer Incidence in Five Continents, Vol. VII. Lyon: IARC Scientific Publication; 1997.
2. Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB,. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 2004; 57: 595-602.
3. Chin D, Boyle GM, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005; 113: 789-797.
4. Hardisson D,. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003; 260: 502-508.
5. Papadimitrakopulou VA,. Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr Opin Oncol 2000; 12: 240-245.
6. Fletcher CDM, editor. Diagnostic histopathology of tumors. 2nd edition. London: Churchill-Livingstone; 2000.
7. Shah JP,. Head and Neck Surgery and Oncology. 3rd edition. Edinburgh: Mosby; 2003.
8. Rhys Evans PH, Montgomery PQ, Gullane PJ, editors. Principles and Practice of Head and Neck Oncology. 1st edition. London: Martin Dunitz; 2003.
9. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94: 1914-1918.
10. Knuth A, Jäger D, Jäger E,. Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol 2000; 46 Suppl: S46-51.
11. Jäger D, Jäger E, Knuth A,. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54: 669-674.
12. Bodey B,. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2002; 2: 577-584.
13. Renkvist N, Castelli C, Robbins PF,. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 3-15.
14. Herman J, van der Bruggen P, Luescher IF, et al. A peptide encoded by the human MAGE3 gene are presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996; 43: 377-383.
15. Jungbluth AA, Busam KJ, Kolb D, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000; 85: 460-465.
16. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S,. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001; 61: 5544-5551.
17. Hofbauer GF, Schaefer C, Noppen C, et al. MAGE-3 immunoreactivity in formalid-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151: 1549-1553.
18. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT,. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22-32.
19. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G,. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182: 323-331.
20. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U,. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9: 4296-4303.
21. Brasseur F, Rimoldi D, Liénard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 375-380.
22. Juretić A, Kneǎević F, Spagnoli GC, et al. Expression of MAGE-1, -2 and -3 genes in primary and metastatic lesions of human malignant melanomas. Croat Med J 1996; 37: 119-122.
23. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B,. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003; 4: 104-109.
24. Kavalar R, Sarcevic B, Spagnoli GC, et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch 2001; 439: 127-131.
25. Kocher T, Zheng M, Bolli M, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of urinary bladder: a tissue microarray study. Int J Cancer 2002; 100: 702-705.
26. Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002; 236: 785-793; discussion 793.
27. Kienstra MA, Neel HB, Strome SE, Roche P,. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003; 25: 457-463.
28. Eura M, Ogi K, Chikamatsu K, et al. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 1995; 64: 304-308.
29. Lee KD, Chang HK, Jo YK, et al. Expression of MAGE 3 gene product in squamous cell carcinomas of the head and neck. Anticancer Res 1999; 19: 5037-5042.
30. Atanackovic D, Blum I, Cao Y, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 2006; 5: 1218-1225.
31. Landry C, Brasseur F, Spagnoli GC, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000; 86: 835-841.
32. Bolli M, Schultz-Thater E, Zajac P, et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 2005; 115: 960-966.
33. Schultz-Thater E, Noppen C, Gudat F, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 2000; 83: 204-208.
34. Quon H, Liu FF, Cummings BJ,. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-159.
35. Lucas S, Coulie PG,. About human tumor antigens to be used in immunotherapy. Semin Immunol 2008; 20: 301-307.
36. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009; 15: 2166-2173.
37. Yuan J, Gnjatic S, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008; 105: 20410-20415.
38. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
39. Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42.
40. Fujita S, Wada H, Jungbluth AA, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10: 6551-6558.